Table 1.

Inhibition of Patient's Autoantibody Activity by Pooled Normal IgM Preparations

Patient's Autoantibody*Inhibitor/IgG Ratio (mol/mol)% of Inhibition of IgG Autoantibody Activity by
IVIgF(ab′)2 of IVIgIVgMMonoclonal IgM
Anti-S Ag 1 22 25 40 0 
 2 42 43 57 0 
Anti-vWF 5 12 10 33 0 
 10 31 31 36 0 
Anti-FVIII 10 15 11 29 0 
 25 23 12 34 2 
Patient's Autoantibody*Inhibitor/IgG Ratio (mol/mol)% of Inhibition of IgG Autoantibody Activity by
IVIgF(ab′)2 of IVIgIVgMMonoclonal IgM
Anti-S Ag 1 22 25 40 0 
 2 42 43 57 0 
Anti-vWF 5 12 10 33 0 
 10 31 31 36 0 
Anti-FVIII 10 15 11 29 0 
 25 23 12 34 2 
*

The binding of 125I-labeled IgG purified from serum of patients with Birdshot retinochoroidopathy, anti-vWF, and anti-FVIII autoimmune disease to the corresponding antigens was assessed in the absence or in the presence of increasing amounts of competing inhibitor Ig. Competing Ig was IVIgM, monoclonal IgM, IVIg, and F(ab′)2 fragments of IVIg. The range of concentration of inhibitors was between 2 μg/mL and 1 mg/mL. The molar ratios between inhibitor and patient's IgG at which dose-dependent inhibition of binding was observed are indicated together with the percentage of inhibition of autoantibody activity.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal